DESTINY-Breast05: Trastuzumab deruxtecan performs well in high-risk HER2+ early BC Presented ByProf. Charles Geyer, University of Pittsburgh, PA, USA ConferenceESMO 2025 TypeNews article 15 December 2025 12:42